Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase...

Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes
Phase I Clinical Study

GOTHENBORG, Sweden, July 14 /PRNewswire/ -- PharmaSurgics AB.
successfully completes Phase I clinical study showing their novel candidate
drug PXL01 is safe and well tolerated. Initially developed to prevent
post-surgical adhesion formation following hand surgery the product combines
the pharmacological effect of PXL01 with the physical barrier effect of the
vehicle, and has the potential to be the first anti-adhesion drug on the
market. 'These results provide the foundation for proceeding to the next
phase, proof of concept study in patients,' said Fredrik Sjovall, CEO of
PharmaSurgics, adding 'the proof of concept study in patients of flexor
tendon repair surgery is scheduled to start in December 2009.'
Post-surgical adhesions are bands of scar tissue connecting anatomic
sites in the body that should not normally be connected. These develop after
almost every type of surgery and cause symptoms such as restricted joint
mobility, chronic pain, intestinal obstruction and re-operative
complications. Following flexor tendon repair surgery post-surgical adhesions
lead to decreased strength and function of the affected joints, extensive
post-operative physiotherapy and extended periods of sick leave.
About PharmaSurgics
PharmaSurgics in Sweden AB is a Gothenburg based biotech company that
develops and commercializes a novel treatment for preventing harmful scarring
and promoting wound healing after surgery. PharmaSurgics product concept is
based on proprietary synthetic peptides which have strong anti-inflammatory
and anti-infectious properties. The company was founded in 2005, based on
extensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarker
at Sahlgrenska University Hospital, Gothenborg, Sweden. PharmaSurgics is a
Karolinska Development portfolio company.
For further information please contact
Fredrik Sjovall, CEO of PharmaSurgics
Ph: +46-31-762-29-01
Email: fredrik@pharmasurgics.se

SOURCE PharmaSurgics AB

For further information please contact: Fredrik Sjovall, CEO of PharmaSurgics,
Ph: +46-31-762-29-01, Email: fredrik@pharmasurgics.se